TrialClinical and translational science2026

A Randomized Phase 1 Study Comparing the PK, PD, Safety, and Immunogenicity of Proposed Biosimilar RGB-14-X and Denosumab in Healthy Adult Males.

Emmanuel Biver et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.